Recent News for TGTX - TG Therapeutics, Inc.

Date Title
Jan 17 The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
Jan 16 ACB, MS among premarket gainers
Jan 16 TG Therapeutics initiates umbralisib application in U.S.
Jan 16 TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
Jan 16 The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
Jan 10 Options Traders Expect Huge Moves in TG Therapeutics (TGTX) Stock
Jan 10 TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 9 The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results
Dec 27 31 Healthcare Stocks Moving In Friday's Pre-Market Session
Dec 24 TG Therapeutics (TGTX) Catches Eye: Stock Jumps 8.9%
Dec 24 The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
Dec 23 TG Therapeutics launches $50M registered direct offering
Dec 23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor
Dec 18 Revisiting TG Therapeutics
Dec 13 TG Therapeutics (TGTX) Investor Presentation - Slideshow
Dec 13 Sarepta Therapeutics leads healthcare gainers; OncoSec Medical among losers
Dec 10 Hedge Funds Are Crazy About TG Therapeutics Inc (TGTX)
Dec 10 TG Therapeutics' Shares Soar on Positive Early-Stage Data
Dec 10 The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
Dec 9 Kinase inhibitors in focus after Merck bid for ArQule
Dec 9 BLUE, PCG among premarket gainers
Dec 9 TG Therapeutics shares rise on early-stage clinical data
Dec 9 38 Healthcare Stocks Moving In Monday's Pre-Market Session
Dec 9 TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition
Dec 9 TG Therapeutics up 24% premarket on positive data on triple combo in leukemia

Back to the Main TGTX Page...